miR‑494 inhibits cell proliferation and metastasis via targeting of CDK6 in osteosarcoma

Yuan,Wei; Wang,Du; Liu,Yang; Tian,Dongdong; Wang,Yang; Zhang,Ranxi; Yin,Liangjun; Deng,Zhongliang

doi:10.3892/mmr.2017.7709

miR‑494 inhibits cell proliferation and metastasis via targeting of CDK6 in osteosarcoma

Authors:
- Wei Yuan
- Du Wang
- Yang Liu
- Dongdong Tian
- Yang Wang
- Ranxi Zhang
- Liangjun Yin
- Zhongliang Deng
View Affiliations

Affiliations: Department of Orthopedic Surgery, The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, P.R. China, Department of Orthopedics, Wuhan Hospital No. 3 and Tongren Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: October 4, 2017 https://doi.org/10.3892/mmr.2017.7709
Pages: 8627-8634
Copyright: © Yuan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumorigenesis is a multistep process involving various cell growth‑associated factors. Accumulated evidence indicates that the disordered regulation of microRNAs (miRNAs) contributes to tumorigenesis. However, the detailed mechanism underlying the involvement of miRNAs in oncogenesis remains to be fully elucidated. In the present study, the repressed expression of microRNA (miR)‑494 was identified in 18 patients with osteosarcoma (OS) and OS cell lines, compared with corresponding controls. To determine whether deregulated miR‑494 exerts tumor‑suppressive effects in the development of OS, the effects of miR‑494 on cell proliferation and metastasis were evaluated. It was found that the restoration of miR‑494 in MG‑63 and U2OS cells led to inhibited cell proliferation and attenuated migratory propensity in vitro, determined through analysis using MTT, colony formation and Transwell assays. In addition, overexpression of miR‑494 markedly suppressed the tumor volume and weight in vivo. In accordance, the ectopic expression of miR‑494 induced cell cycle arrest at the G1/S phase in OS cells. Bioinformatics analysis and luciferase reporter assays were performed to investigate the potential regulatory role of miR‑494, the results of which indicated that miR‑494 directly targeted cyclin‑dependent kinase 6 (CDK6). Of note, the data obtained through reverse transcription‑quantitative polymerase chain reaction and western blot analyses suggested that the elevated expression of miR‑494 resulted in reduced mRNA and protein expression levels of CDK6. Taken together, these findings indicated that the miR‑494/CDK6 axis has a significant tumor‑suppressive effect on OS, and maybe a diagnostic and therapeutic target for the treatment of OS.

View Figures

View References

1	Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment-where do we stand? A state of the art review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
2	Benjamin RS: Osteosarcoma: Better treatment through better trial design. Lancet Oncol. 16:12–13. 2015. View Article : Google Scholar : PubMed/NCBI
3	Xiong Y, Wu S, Du Q, Wang A and Wang Z: Integrated analysis of gene expression and genomic aberration data in osteosarcoma (OS). Cancer Gene Ther. 22:524–529. 2015. View Article : Google Scholar : PubMed/NCBI
4	Lulla RR, Costa FF, Bischof JM, Chou PM, de F, Bonaldo M, Vanin EF and Soares MB: Identification of differentially expressed micrornas in osteosarcoma. Sarcoma. 2011:7326902011. View Article : Google Scholar : PubMed/NCBI
5	Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
6	Romano F, Garancini M and Uggeri F, Degrate L, Nespoli L, Gianotti L, Nespoli A and Uggeri F: Surgical treatment of liver metastases of gastric cancer: State of the art. World J Surg Oncol. 10:1572012. View Article : Google Scholar : PubMed/NCBI
7	Olaru AV, Ghiaur G, Yamanaka S, Luvsanjav D, An F, Popescu I, Alexandrescu S, Allen S, Pawlik TM, Torbenson M, et al: MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology. 54:2089–2098. 2011. View Article : Google Scholar : PubMed/NCBI
8	Hong KJ, Wu DC, Cheng KH, Chen LT and Hung WC: RECK inhibits stemness gene expression and tumorigenicity of gastric cancer cells by suppressing ADAM-mediated Notch1 activation. J Cell Physiol. 229:191–201. 2014. View Article : Google Scholar : PubMed/NCBI
9	Ma YB, Li GX, Hu JX, Liu X and Shi BM: Correlation of miR-494 expression with tumor progression and patient survival in pancreatic cancer. Genet Mol Res. 14:18153–18159. 2015. View Article : Google Scholar : PubMed/NCBI
10	Tian C, Zheng G, Zhuang H, Li X, Hu D, Zhu L, Wang T, You MJ and Zhang Y: MicroRNA-494 activation suppresses bone marrow stromal cell-mediated drug resistance in acute myeloid leukemia cells. J Cell Physiol. 232:1387–1395. 2017. View Article : Google Scholar : PubMed/NCBI
11	Lim L, Balakrishnan A, Huskey N, Jones KD, Jodari M, Ng R, Song G, Riordan J, Anderton B, Cheung ST, et al: MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. Hepatology. 59:202–215. 2014. View Article : Google Scholar : PubMed/NCBI
12	Zhao X, Zhou Y, Chen YU and Yu F: miR-494 inhibits ovarian cancer cell proliferation and promotes apoptosis by targeting FGFR2. OncolLett. 11:4245–4251. 2016.
13	Yuan J, Wang K and Xi M: miR-494 inhibits epithelial ovarian cancer growth by targeting c-Myc. Med Sci Monit. 22:617–624. 2016. View Article : Google Scholar : PubMed/NCBI
14	Tian C, Zheng G, Zhuang H, Li X, Hu D, Zhu L, Wang T, You MJ and Zhang Y: MicroRNA-494 activation suppresses bone marrow stromal cell-mediated drug resistance inacute myeloid leukemia cells. J Cell Physiol. 232:1387–1395. 2017. View Article : Google Scholar : PubMed/NCBI
15	Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ, et al: Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 19:6173–6182. 2013. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M and Rajewsky N: Combinatorial microRNA target predictions. Nat Genet. 37:495–500. 2005. View Article : Google Scholar : PubMed/NCBI
18	Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. Elife. 4:2015. View Article : Google Scholar
19	Griffiths-Jones S, Saini HK, van Dongen S and Enright AJ: miRBase: Tools for microRNA genomics. Nucleic Acids Res. 36(Database issue): D154–D158. 2008.PubMed/NCBI
20	Liu S and Feng P: miR-203 determines poor outcome and suppresses tumor growth by targeting tbk1 in osteosarcoma. Cell Physiol Biochem. 37:1956–1966. 2015. View Article : Google Scholar : PubMed/NCBI
21	Vanas V, Haigl B, Stockhammer V and Sutterlüty-Fall H: MicroRNA-21 increases proliferation and cisplatin sensitivity of osteosarcoma-derived cells. PLoS One. 11:e01610232016. View Article : Google Scholar : PubMed/NCBI
22	Yao J, Qin L, Miao S, Wang X and Wu X: Overexpression of miR-506 suppresses proliferation and promotes apoptosis of osteosarcoma cells by targeting astrocyte elevated gene-1. Oncol Lett. 12:1840–1848. 2016.PubMed/NCBI
23	Li Y, Liu J, Liu ZZ and Wei WB: MicroRNA-145 inhibits tumour growth and metastasis in osteosarcoma by targeting cyclin-dependent kinase, CDK6. Eur Rev Med Pharmacol Sci. 20:5117–5125. 2016.PubMed/NCBI
24	Roscigno G, Puoti I, Giordano I, Donnarumma E, Russo V, Affinito A, Adamo A, Quintavalle C, Todaro M, Vivanco MD and Condorelli G: miR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer. Oncotarget. 8:19507–19521. 2017.PubMed/NCBI
25	Zhu D, Tu M, Zeng B, Cai L, Zheng W, Su Z and Yu Z: Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2. Cancer Med. 6:452–462. 2017. View Article : Google Scholar : PubMed/NCBI
26	Shyamasundar S, Lim JP and Bay BH: miR-93 inhibits the invasive potential of triple-negative breast cancer cells in vitro via protein kinase WNK1. Int J Oncol. 49:2629–2636. 2016. View Article : Google Scholar : PubMed/NCBI
27	Huang S, Li X and Zhu H: MicroRNA-152 targets phosphatase and tensin homolog to inhibit apoptosis and promote cell migration of nasopharyngeal carcinoma cells. Med Sci Monit. 22:4330–4337. 2016. View Article : Google Scholar : PubMed/NCBI
28	Qu Y, Pan S, Kang M, Dong R and Zhao J: MicroRNA-150 functions as a tumor suppressor in osteosarcomaby targeting IGF2BP1. Tumour Biol. 37:5275–5284. 2016. View Article : Google Scholar : PubMed/NCBI
29	Jiang X, Li X, Wu F, Gao H, Wang G, Zheng H, Wang H, Li J and Chen C: Overexpression of miR-92a promotes the tumor growth of osteosarcoma by suppressing F-box and WD repeat-containing protein 7. Gene. 606:10–16. 2017. View Article : Google Scholar : PubMed/NCBI
30	Shen PF, Chen XQ, Liao YC, Chen N, Zhou Q, Wei Q, Li X, Wang J and Zeng H: MicroRNA-494-3p targets CXCR4 to suppress the proliferation, invasion and migration of prostate cancer. Prostate. 74:756–767. 2014. View Article : Google Scholar : PubMed/NCBI
31	Zhao XQ, Liang TJ and Fu JW: miR-494 inhibits invasion and proliferation of gastric cancer by targeting IGF-1R. Eur Rev Med Pharmacol Sci. 20:3818–3824. 2016.PubMed/NCBI
32	Handschick K, Beuerlein K, Jurida L, Bartkuhn M, Müller H, Soelch J, Weber A, Dittrich-Breiholz O, Schneider H, Scharfe M, et al: Cyclin-dependent kinase 6 is a chromatin-bound cofactor for NF-κB-dependent gene expression. Mol Cell. 53:193–208. 2014. View Article : Google Scholar : PubMed/NCBI
33	Wiedemeyer WR, Dunn IF, Quayle SN, Zhang J, Chheda MG, Dunn GP, Zhuang L, Rosenbluh J, Chen S, Xiao Y, et al: Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Proc Natl Acad Sci USA. 107:pp. 11501–11506. 2010; View Article : Google Scholar : PubMed/NCBI
34	Tsai JW, Li CF, Kao YC, Wang JW, Fang FM, Wang YH, Wu WR, Wu LC, Hsing CH, Li SH, et al: Recurrent amplification at 7q21.2 Targets CDK6 gene in primary myxofibrosarcomas and identifies CDK6 overexpression as an independent adverse prognosticator. Ann Surg Oncol. 19:2716–2725. 2012. View Article : Google Scholar : PubMed/NCBI